Corbus Pharmaceuticals Holdings, Inc. (CRBP)
11.21
-0.25
(-2.18%)
USD |
NASDAQ |
Sep 04, 14:21
Corbus Pharmaceuticals Holdings Enterprise Value : 100.30M for Sept. 3, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 03, 2026 | 100.30M |
| September 02, 2026 | 100.67M |
| September 01, 2026 | 96.94M |
| August 31, 2026 | 90.03M |
| August 28, 2026 | 90.03M |
| August 27, 2026 | 94.14M |
| August 26, 2026 | 97.31M |
| August 25, 2026 | 97.50M |
| August 24, 2026 | 85.92M |
| August 21, 2026 | 80.13M |
| August 20, 2026 | 70.05M |
| August 19, 2026 | 72.85M |
| August 18, 2026 | 74.53M |
| August 17, 2026 | 82.19M |
| August 14, 2026 | 74.72M |
| August 13, 2026 | 74.53M |
| August 12, 2026 | 68.56M |
| August 11, 2026 | 63.89M |
| August 10, 2026 | 62.96M |
| August 07, 2026 | 76.21M |
| August 06, 2026 | 68.18M |
| August 05, 2026 | 65.01M |
| August 04, 2026 | 61.84M |
| August 03, 2026 | 52.87M |
| July 31, 2026 | 53.81M |
| Date | Value |
|---|---|
| July 30, 2026 | 55.30M |
| July 29, 2026 | 52.87M |
| July 28, 2026 | 55.95M |
| July 27, 2026 | 55.86M |
| July 24, 2026 | 57.54M |
| July 23, 2026 | 60.34M |
| July 22, 2026 | 51.38M |
| July 21, 2026 | 53.99M |
| July 20, 2026 | 52.31M |
| July 17, 2026 | 54.55M |
| July 16, 2026 | 50.63M |
| July 15, 2026 | 54.55M |
| July 14, 2026 | 54.93M |
| July 13, 2026 | 55.11M |
| July 10, 2026 | 67.06M |
| July 09, 2026 | 66.69M |
| July 08, 2026 | 64.64M |
| July 07, 2026 | 61.46M |
| July 06, 2026 | 54.37M |
| July 02, 2026 | 59.03M |
| July 01, 2026 | 55.67M |
| June 30, 2026 | 61.46M |
| June 29, 2026 | 21.90M |
| June 26, 2026 | 17.64M |
| June 25, 2026 | 8.947M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.913B |
| Alnylam Pharmaceuticals, Inc. | 35.05B |
| Anika Therapeutics, Inc. | 267.88M |
| Savara, Inc. | 960.37M |
| Vericel Corp. | 2.003B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -35.04M |
| Total Expenses (Quarterly) | 35.04M |
| EPS Diluted (Quarterly) | -1.805 |
| Earnings Yield | -55.10% |
| Normalized Earnings Yield | -55.10 |